Navigation Links
Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
Date:12/13/2012

y.

Operating ResultsPersonalized Oncology Solutions (POS) revenues were $0.5 million and $0.6 million for the three months ended October 31, 2012 and 2011, respectively, a decrease of $0.1 million, or 17%. For the six months ended October 31, 2012 and 2011, POS revenues were $1.4 million and $1.2 million, respectively, an increase of $0.2 million, or 17%. The increase in POS revenues was driven by an increased number of drug studies completed during the six months ended October 31, 2012 compared to the same period in the previous year. During the six months ended October 31, 2012 and 2011, the Company completed 22 and 5 drug studies, respectively.  These increases are the result of the steady increase in the number of TumorGrafts performed which have moved onto drug studies.

POS cost of sales was $0.6 million and $0.5 million for the three months ended October 31, 2012 and 2011, respectively, an increase of $0.1 million, or 20%. For the six months ended October 31, 2012 and 2011, POS cost of sales was $1.4 million and $0.9 million, respectively, an increase of $0.5 million, or 56%. For the three months ended October 31, 2012 and 2011, gross margins for POS were -20% and 17%, respectively. For the six months ended October 31, 2012 and 2011, gross margins for POS were 0% and 25%, respectively.  The increases in cost of sales and the declines in gross margins can be attributed to increased volumes of implants and drug studies performed, in line with management's strategy to obtain more tumors to increase our tumor model offerings to our TOS sponsors and increase the number of models in our Tumorbank 

Translational Oncology Solutions (TOS) revenues were $1.0 million and $1.2 million for the three months ended October 31, 2012 and 2011, respectively, a decrease of $0.2 million, or 17%. The decrease in TOS revenues was due primarily to decreased contract bookings in the previous quarters. TOS revenues were $2.2 million for each of the
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
3. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
8. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
9. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
10. International Oncology Innovators Meeting in Hamburg
11. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... Mass. , April 16, 2015  In recognition of ... collaborated with hemophilia advocacy groups to illuminate more than 15 ... , including Boston,s Zakim Bridge and ... New Orleans, Mercedes-Benz Superdome and ... occur during the evening of April 17, and coincide with ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... the state of Wisconsin improperly apply its five percent sales ... ? , ,The Wisconsin Supreme Court will decide ... and there is an estimated $350 million at stake for ... issue is the definition of modified software, which unlike off-the-shelf ...
... merits of electronic medical records and other healthcare information technology from ... industry's electronic push? Marty Preizler, president and CEO of Physicians ... way and he explains why in Part I of a recent ... are as follows: , , WTN: From the perspective ...
... nitch or the more cosmopolitan neesh, the term niche is ... the Internet, it increasingly spells growth and profit. , ,An ... what some are calling a seismic shift toward niche products, ... as the way to move the Earth. , ,Perhaps no ...
Cached Biology Technology:Visions: Preizler offers insurer's perspective on healthcare IT 2Visions: Preizler offers insurer's perspective on healthcare IT 3Visions: Preizler offers insurer's perspective on healthcare IT 4Visions: Preizler offers insurer's perspective on healthcare IT 5Visions: Preizler offers insurer's perspective on healthcare IT 6Visions: Preizler offers insurer's perspective on healthcare IT 7Internet-enabled niche markets take center stage 2Internet-enabled niche markets take center stage 3
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... news clip that aired this week on Washington ... In a segment "The Next Great Thing", host ... new way to pay, and ,a really big breakthrough in ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... The success of long term hip replacement surgery may lie ... the Annals of the Rheumatic Diseases. , The researchers analysed ... (162) had problems after hip replacement in the 10 years ... early signs of ÔÇťaseptic loosening,?which describes a condition in which ...
... that the clouded leopard found on the islands of Borneo ... secretive rainforest animal was originally thought to be the same ... , Genetic analysis conducted at the U.S. National Cancer ... species is comparable to the differences between other large cat ...
... of Medicine and Pharmacology at the University of California, ... 265 twin pairs over the past few years, which ... studying many traits and genes, we have started to ... genetic variations in twins provides scientists with data on ...
Cached Biology News:New species declared: Clouded leopard on Borneo and Sumatra 2Twin studies reveal genetic components leading to cardiac and kidney disease 2Twin studies reveal genetic components leading to cardiac and kidney disease 3
...
... StabilZyme SELECT Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... contains a combination of 0.02% methylisothiazolone and ... SELECT Stabilizer is a diluent and stabilizer ...
... designed to stabilize the biomolecules during ... There are neither animal proteins ... a convenient 10 times solution in ... to other traditional lyophilizing additives such ...
... CERTOMAT IS, a true benchtop incubator-shaker, has the ... Having a footprint of 540 x 680 mm ... incubation chamber (370 x 505 x 510mm). Available ... CERTOMAT IS is ideal for shaking applications requiring ...
Biology Products: